How does TMCI's EPS trend compare to industry peers?

Treace Medical (TMCI) does not currently have EPS data available for the most recent quarter (2024Q4). However, when comparing the available EPS figures for TMCI's industry peers, it is important to note that TMCI's comparison is primarily with Boston Scientific (BSX), as all other peers (Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT)) have EPS data for 2024Q4:

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|ABT|ABT.N|Abbott Laboratories|2024 Q1|0.7|169|
|MDT|MDT.N|Medtronic|2024 Q1|0.59|169|
|TMCI|TMCI.O|Treace Medical|2024 Q1|-0.3|185|
|SYK|SYK.N|Stryker|2024 Q1|2.05|169|
|BSX|BSX.N|Boston Scientific|2024 Q1|0.33|169|
|ISRG|ISRG.O|Intuitive Surgical|2024 Q1|1.51|185|
|ABT|ABT.N|Abbott Laboratories|2024 Q2|0.74|169|
|MDT|MDT.N|Medtronic|2024 Q2|0.68|169|
|TMCI|TMCI.O|Treace Medical|2024 Q2|-0.34|185|
|SYK|SYK.N|Stryker|2024 Q2|2.14|169|

Given that TMCI's EPS trend is not currently available, we can only compare the EPS figures for the other five companies. It is clear that TMCI's potential EPS would need to be significantly higher than BSX's $0.38 to stand out in the industry, given that all other peers (ABT, ISRG, SYK, and MDT) have higher EPS figures.